EAGAN, MN – June 6, 2005 – Research on Biothera’s immune therapy will be presented June 8-11 in Philadelphia at the fourth annual Era of Hope meeting for the Department of Defense Breast Cancer Research Program (BCRP).

Era of Hope is one of the premiere breast cancer research conferences in the U.S. This year’s meeting will highlight the multidisciplinary and innovative approaches funded by the BCRP in its efforts to eradicate breast cancer.

Biothera scientific advisor Jun Yan, MD, PhD, will present the research on behalf of his colleagues at the Tumor Immunobiology Program at the James Graham Brown Cancer Center, University of Louisville. Their paper is entitled, “Beta-Glucans Augment the Killing of Activity of Anti-Tumor Monoclonal Antibodies by Providing a Novel Mechanism that Primes Neutrophil CR3 to Kill Antibody Targeted Tumor Cells.”

Biothera is developing patented beta glucan compounds as pharmaceuticals to fight breast and other types of cancer. The company is schedule to begin clinical testing of its intravenous compound later this year.

About Biothera, the Immune Health Company
Biothera is a biotechnology company dedicated to improving immune health. The company's primary focus is developing pharmaceuticals whose unique mechanism of action engages immune cells not normally involved in the fight against cancer. In addition, Biothera’s healthcare group manufactures and markets food-grade immune-enhancing ingredients for the nutritional supplement, functional food, cosmetic and the animal feed and nutrition markets.

Contact:
David Walsh
VP, Communications
Biothera, the Immune Health Company
651-256-4606
dwalsh@biotherapharma.com